





000

000000

000000

00000  
® 000  
00000  
00000

○ 000000000000000000 IGF-I 00000000-C 000000000000000000000000: 0000000000000000  
0

○ 000000000000000000

○ 000000000000000000

000000000  
000000000  
000000000  
000000000  
000000000  
0000000  
090mg 4  
03  
000000000  
000000000  
0000  
060mg 90mg  
0120mg  
04  
00  
000000000  
000000000  
000000000  
0000  
0120mg 4  
000000000  
0000000



0000  
® 0000  
0  
00000  
00

- 00000000000000000000
- 00000000000000000000
- 0000000000

00000000  
 0000000000  
 00000000  
 0000000000  
 00000000  
 000000001  
 01050mg  
 04000000  
 000000002  
 00000000  
 00100000  
 0000000000  
 00000000  
 00000000  
 00  
 0000000000  
 00000000  
 000000001  
 01  
 037.5mg  
 00000000  
 00000000  
 00000000  
 000101  
 050mg000  
 00000

0000®  
0000  
0000  
0000

0000000000000000

00000000  
00000000  
00  
1.500000  
00000000  
00000000  
000001  
0500mg/m<sup>2</sup>  
00000001  
01050000  
0000000000  
3700000000  
00010000  
00000000  
000  
2.100000  
00000000  
00000000  
000001  
01,000mg/m<sup>2</sup>  
00000001  
00000101  
00000000  
00000000  
00000000  
00000000  
000000010  
0000  
01,500mg/m<sup>2</sup>  
00000000  
000000

0000®  
00  
0000  
0000  
0000  
0<sup>177</sup>Lu00

000000000000000000000000

00000000  
00000000  
00000  
0<sup>177</sup>Lu000  
01  
07.4GBq  
03000008  
00000004  
00000000  
00000000  
00000000  
0000

000000002022030000

\*1 Yao JC, Shah MH, Ito T, et al. N Engl J Med. 2011; 364: 514-523.  
\*2 Yao JC, et al. Lancet 2016; 387: 968-977.  
\*3 Rinke A, et al. J Clin Oncol. 2009; 27: 4656-4663.  
\*4 Fjällskog ML, et al. Cancer. 2001; 92050: 1101-1107.  
\*5 Kulke MH, et al. Dig Dis Sci. 2006; 51060: 1033-1038.  
\*6 Caplin ME, et al. N Engl J Med. 2014; 371030: 224-233.

□□□□□□□□□□□□□□□□

□□□□□□

---

**Source URL:** [https://prod.pro.novartis.com/jp-ja/products/afinitor/net/therapy\\_02](https://prod.pro.novartis.com/jp-ja/products/afinitor/net/therapy_02)